The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2013;(3): 42‑57

Read: 5264 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2013;(3):42‑57. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360- leaflets 1420.
  2. Hendriks J.M., de Wit R., Crijns H.J., et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 2012;33:2692-2699.
  3. Berti D., Hendriks J.M., Brandes A., et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert pro- grammes as a way to structure daily practice. Eur Heart J 2013;doi:10.1093/eurheartj/eht096. [first published online March 21, 2013].
  4. van Ryn J., Baruch L., Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012;125:417-420.
  5. van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-1127.
  6. Huisman M.V., Lip G.Y., Diener H.C., et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-847.
  7. Huisman M.V., Lip G.Y., Diener H.C., et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-847.
  8. Mueck W., Lensing A.W., Agnelli G., et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50:675-686.
  9. Gnoth M.J., Buetehorn U., Muenster U., et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011;338:372-380.
  10. Mueck W., Kubitza D., Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Brit J Clin Pharmacol (2013; EPub ahead of print; doi 10.1111/bcp.12075).
  11. Wang L., Zhang D., Raghavan N., et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38:448-458.
  12. Blech S., Ebner T., Ludwig-Schwellinger E., et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-399.
  13. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817.
  14. Lahaye S.A., Gibbens S.L., Ball D.G., et al. A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur Heart J 2012;33:2163-2171.
  15. Mendell J., Tachibana M., Shi M., Kunitada S. Effects of food on the pharmacokin- etics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 2011;51:687-694.
  16. Stangier J., Stahle H., Rathgen K., Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59.
  17. Liesenfeld K.H., Lehr T., Dansirikul C., et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9:2168-2175.
  18. Ruff C.T., Giugliano R.P., Antman E.M., et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-641.
  19. Dans A.L., Connolly S.J., Wallentin L., et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127:634-640.
  20. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
  21. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
  22. Bae J.P., Dobesh P.P., Klepser D.G., et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012;18:139-146.
  23. Laliberte F., Nelson W.W., Lefebvre P., et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-690.
  24. Olesen J.B., Lip G.Y.H., Kamper A.-L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-635.
  25. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-2830.
  26. Piccini J.P., Stevens S.R., Chang Y., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation 2013;127:224-232.
  27. Camm A.J., Savelieva I. "R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation. Circulation 2013;127:169-171.
  28. Marinigh R., Lane D.A., Lip G.Y. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011;57:1339-1348.
  29. Camm A.J., Lip G.Y., De Caterina R., et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
  30. Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-2394.
  31. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
  32. Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-2372.
  33. Kubitza D., Becka M., Roth A., Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-2765.
  34. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
  35. Ogata K., Mendell-Harary J., Tachibana M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-753.
  36. Furugohri T., Isobe K., Honda Y., et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008;6:1542-1549.
  37. Raghavan N., Frost C.E., Yu Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos, Biol Fate Chem 2009;37:74-81.
  38. Kubitza D., Becka M., Zuehlsdorf M., Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46: 549-558.
  39. Moore K.T., Plotnikov A.N., Thyssen A., et al. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol 2011;58:581-588.
  40. Levi M., Eerenberg E., Kamphuisen P.W. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemos 2011;9:1705-1712.
  41. Warkentin T.E., Margetts P., Connolly S.J., et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012;119:2172-2174.
  42. Wanek M.R., Horn E.T., Elapavaluru S., et al. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012;46:e21.
  43. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-268.
  44. Zhou W., Schwarting S., Illanes S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011;42:3594-3599.
  45. Lambourne M.D., Eltringham-Smith L.J., Gataiance S., et al. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemos 2012;10:1830-1840.
  46. Pragst I., Dörr B., Kaspereit F., et al. Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits. Pathophysiol Haemost Thromb 2010;37(Suppl 1):A94.
  47. Pragst I., Zeitler S.H., Doerr B., et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemos 2012;10:1841-1848.
  48. Godier A., Miclot A., Le Bonniec B., et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012;116:94-102.
  49. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-1579.
  50. Marlu R., Hodaj E., Paris A., et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemos 2012; 108:217- 224.
  51. Escolar G., Arellano-Rodrigo E., Reverter J.C., et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. AHA Emerging Science Series, June 20, 2012. Circulation 2012;126:520-521 (Abstract).
  52. van Ryn J., Ruehl D., Priepke H., et al. Reversibility of the anti- coagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008;93(Suppl 1):148.
  53. Healey J.S., Eikelboom J., Douketis J., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY Randomized Trial. Circulation 2012;126:343-348.
  54. Sie P., Samama C.M., Godier A., et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011;104:669-676.
  55. Torn M., Rosendaal F.R. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003;123:676-682.
  56. Lakkireddy D., Reddy Y.M., Di Biase L., et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012;59:1168-1174.
  57. Kaseno K., Naito S., Nakamura K., et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012;76:2337-2342.
  58. Snipelisky D., Kauffman C., Prussak K., et al. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol 2012;35:29-33.
  59. Winkle R.A., Mead R.H., Engel G., et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012;23:264-268.
  60. Kim J.S., She F., Jongnarangsin K., et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm (EPub ahead of print, March 2013, doi: 10.1016/j.hrthm.2012.12.011).
  61. Lopes R.D., Pieper K.S., Horton J.R., et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart 2008;94:867-873.
  62. Lopes R.D., Elliott L.E., White H.D., et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 2009;30:2019-2028.
  63. Lopes R.D., Starr A., Pieper C.F., et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med 2010;123:134-140.
  64. Rothberg M.B., Celestin C., Fiore L.D., et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-250.
  65. Hurlen M., Abdelnoor M., Smith P., et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-974.
  66. Fiore L.D., Ezekowitz M.D., Brophy M.T., et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial in- farction: primary results of the CHAMP study. Circulation 2002;105:557-563.
  67. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investi- gators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001;37:475-484.
  68. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double- blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-396.
  69. Sorensen R., Hansen M.L., Abildstrom S.Z, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009;374:1967-1974.
  70. Lamberts M., Olesen J.B., Ruwald M.H., et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012;126:1185-1193.
  71. Dewilde W.J., Oirbans T., Verheugt F.W., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, ran- domised, controlled trial. Lancet 2013;381:1107-1115.
  72. Oldgren J., Budaj A., Granger C.B., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-2789.
  73. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
  74. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
  75. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402.
  76. Hohnloser S.H., Oldgren J., Yang S., et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125:669-676.
  77. Karjalainen P.P., Vikman S., Niemela M., et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008;29:1001-1010.
  78. Hamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
  79. De Caterina R., Husted S., Wallentin L., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012;59:1413-1425.
  80. Fox K.A., Dabbous O.H., Goldberg R.J., et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). Brit Med J 2006;333:1091-1094.
  81. Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945.
  82. Nagarakanti R., Ezekowitz M.D., Oldgren J., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-136.
  83. Flaker G., Lopes R., Al-Khatib S., et al. Apixaban and warfarin are associated with a low risk of stroke following cardioversion for AF: Results from the ARISTOTLE Trial. Eur Heart J 2012;33(Abstract Supplement):686.
  84. Piccini J.P., Stevens S. Outcomes following cardioversion and atrial fibrillation ab- lation in patients treated with rivaroxaban and warfarin in the ROCKET-AF trial. Circulation 2012;126(Abstract Supplement, Abstract A19281).
  85. Radberg J.A., Olsson J.E., Radberg C.T. Prognostic parameters in spontaneous intra- cerebral hematomas with special reference to anticoagulant treatment. Stroke 1991;22:571-576.
  86. Morgenstern L.B., Hemphill J.C. 3rd, Anderson C., et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010;41:2108-2129.
  87. Hart R.G., Diener H.C., Yang S., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012;43:1511-1517.
  88. Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes for is- chaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500-1510.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.